Hairy-Cell Leukemia

Dr. Cornely reports receiving grants from the Directorate General for Research and Innovation of the European Commission, the Federal Ministry of Education and Research, and the German Center for Infection Research, receiving contracts from Cidara Therapeutics, F2G, Gilead Sciences, Medpace, MSD, Mundipharma, Octapharma, Pfizer, and Scynexis, receiving consulting fees from AbbVie, AiCuris, Basilea, Biocon, Boston Strategic Partners, Cidara Therapeutics, CSL Seqirus, Elion Therapeutics, Gilead, GSK, IQVIA, Janssen Pharmaceuticals, Matinas Biopharma, Medpace, Melinta Therapeutics, Menarini Group, Molecular Partners, Mundipharma, Mycoses Study Group Education and Research Consortium, Octapharma, Pardes Biosciences, Partner Therapeutics, Pfizer, Population Services International (PSI), Prime Meridian Group, Scynexis, Seres Therapeutics, Shionogi, and TME Pharma (formerly Noxxon Pharma), receiving speaker and lecture honoraria from Abbott, AbbVie, Akademie für Infektionsmedizin, Amedes Group, AstraZeneca, CSL Seqirus, Deutscher Ärzteverlag, Gilead, GSK, Hikma, Ipsen, Medupdate Europe, Moderna, MSD, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Shionogi, Streamed Up, Touch Independent Medical Education, Vitis Pharma, and WebMD, receiving payment for expert testimony from Cidara Therapeutics, participating on a drug review committee for Cidara Therapeutics, IQVIA, PSI, and Pulmocide, participating on a data and safety monitoring board for IQVIA, participating on a data monitoring committee for Janssen Pharmaceuticals, and participating on an advisory board for AstraZeneca, Medpace, Melinta Therapeutics, and Vedanta Biosciences. Dr. Stemler reports receiving grants from Basilea and Noscendo, consulting fees from Mundipharma, and speaker honoraria from AbbVie, Gilead, Hikma, and Pfizer. No other potential conflict of interest relevant to this letter was reported.